Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : CSC-BS0001
Host Cell : CHO-K1 Size : >1x106 frozen cells/vial
| Cat. No. | CSC-BS0001 |
| Description | This cell line is engineered to stably produce Rituximab which is a monoclonal antibody against human MS4A1/CD20. |
| Target Gene | Rituximab |
| Host Cell | CHO-K1 |
| Host Cell Species | Cricetulus griseus (Chinese hamster) |
| Applications |
1. Biosimilar Development 2. Large-Scale Biomanufacturing 3. Preclinical Research 4. Drug Development and Testing |
| Size | >1x106 frozen cells/vial |
| Stability | Validated for at least 10 passages |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Growth Conditions | 37° C, 5% CO2 |
| Storage | Liquid nitrogen |
| Shipping | Dry ice |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
A: Rituximab is a monoclonal antibody commonly used to treat various types of cancer and autoimmune diseases.
A: Rituximab works by binding to the CD20 protein on the surface of cancerous B cells. This binding sets off a chain of events that culminates in the destruction of these cancer cells through a process called antibody-dependent cellular cytotoxicity (ADCC).
A: Rituximab injection is used alone or with other medicines to treat a type of cancer called non-Hodgkin's lymphoma (NHL). It is also used in combination with other anticancer drugs to treat mature B-cell non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-AL).
A: Rituximab, used as a single agent, is very effective in several types of indolent lymphoma, with response rates (RR) of 45% to 60% even in treated patients,1-3 and in more In the aggressive form of NHL, the response rate (RR) is approximately 30%.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
These Rituximab Stable Cell Lines are capable of growing under very specific conditions, which can be easily replicated to maintain consistency across batches.
The CHO-K1 cells can produce high levels of rituximab, making it an ideal platform for commercial production.
Great buy! The Rituximab Stable Cell Line remains effective in targeting the CD20 protein across multiple generations.
The use of these cell lines has allowed for the large-scale production of rituximab. I recommend it.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.